AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+10.2%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$260M
AUM Growth
+$260M
(+19%)
Cap. Flow
+$35.1M
Cap. Flow
% of AUM
13.49%
Top 10 Holdings %
Top 10 Hldgs %
49.44%
Holding
80
New
15
Increased
23
Reduced
13
Closed
6
Top Buys
| 1 |
Merck
MRK
|
$12.8M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$8.05M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$5.57M |
| 4 |
BridgeBio Pharma
BBIO
|
$5.31M |
| 5 |
Cytokinetics
CYTK
|
$4.71M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$5.46M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$5.35M |
| 3 |
Establishment Labs
ESTA
|
$5.25M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
$5.05M |
| 5 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$4.32M |
Sector Composition
| 1 | Healthcare | 92.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Dyne Therapeutics
DYN
$1.92B
| – | – | -92,170 | Closed | -$1.07M |
|